Aim: To examine the outcome and risk factors of biochemical failure (BCF) in Japanese prostate cancer (PCa) patients treated with adjuvant radiotherapy (RT) after radical prostatectomy (RP). Patients and Method: In this study we enrolled 83 Japanese patients having clinically organ-confined PCa without neoadjuvant treatments who received conventional RT (60 Gy) after RP. All patients had extracapsular extension (ECE) and/or positive surgical margin (PSM) of the RP specimens, but no lymph node metastasis. The disease-specific, clinical failure-free, and BCF-free survivals were analyzed. Furthermore, the risk factors affecting the BCF-free survival were examined in detail. Results: The 5-year disease-specific, clinical failure-free, and BCF-free survival rates were 100, 99, and 87%, respectively. The clinicopathological factors associated with BCF were seminal vesicle invasion (SVI) (p = 0.024), perineural invasion (PNI) (p = 0.03), and pre-RT prostate-specific antigen (PSA) (p = 0.014). In the patients with PSM (n = 59), the entire surgical margin-positive patients had a significantly higher risk of BCF than the focal surgical margin-positive patients (p = 0.015). Multivariate analysis showed that SVI and pre-RT PSA were independent prognostic factors of BCF (p = 0.0142, p = 0.0225, respectively). 22% of our patients had only low-grade adverse effects. Conclusion: The outcome of adjuvant RT after RP in the Japanese patients with ECE and/or PSM was excellent, and the adverse effects were mild and tolerable. However, the patients with SVI, PNI, entire surgical margin-positive specimens, or high pre-RT PSA had poor biochemical control by only adjuvant RT after RP.

Keywords:
Prostate cancer, Adjuvant radiotherapy, Radical prostatectomy, Biochemical failure
This content is only available via PDF.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.